ADXS - アドバクシス （Advaxis Inc.） アドバクシスADXSのチャート
ADXSの企業情報
| symbol | ADXS |
|---|---|
| 会社名 | Advaxis Inc （アドバクシス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アドバキシス（Advaxis Inc.）はリステリア・モノサイトゲネス(Lm)-リステリオリシン O(LLO)癌免疫療法の発見・開発・商業化に従事する臨床段階のバイオ技術会社である。これらの免疫療法は、抗原/アジュバント融合タンパク質を分泌する生きた弱毒化Lmバイオエンジニアリングを利用するプラットフォーム技術に基づいている。これらのLm-LLO株は、抗腫瘍T細胞免疫を刺激し、複数のアジュバントの等価物で免疫系を刺激・活性化するために、抗原提示細胞にアクセスして誘導すると同時に複数の機能を単一の免疫療法に統合し、同時にT細胞が腫瘍を排除することを可能にするために腫瘍微小環境における腫瘍保護を低下させる。Axalimogene filolisbacは、ヒトパピローマウイルス関連癌の治療用のリードLm-LLO免疫療法製品候補である。ADXS-PSAは、前立腺癌に関連する前立腺特異抗原（PSA）を標的とするLm-LLO免疫療法製品候補である。 アドバクシスは米国のバイオテクノロジ―企業。がんおよび感染症のための免疫療法の開発に従事。開発中の医薬品は、子宮頸がん、頭頸部がん、肛門がんの治療薬「ADXS-HPV」、前立腺がん向け「ADXS-PSA」、乳がん、胃がんや、ヒトにおける他のがんおよび犬の骨肉腫などのHER2過剰発現がんの治療薬「ADXS-cHER2」の開発を手掛ける。 Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors. |
| 本社所在地 | 305 College Road East Princeton NJ 08540 USA |
| 代表者氏名 | David Sidransky デビッド・シドランスキー |
| 代表者役職名 | Independent chairman of the Board |
| 電話番号 | +1 732-545-1590 |
| 設立年月日 | 31929 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.advaxis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/adxs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -74.67294 |
| 終値（lastsale） | 0.792 |
| 時価総額（marketcap） | 55040158.008 |
| 時価総額 | 時価総額（百万ドル） 58.15208 |
| 売上高 | 売上高（百万ドル） 6.69732 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 18.71808 |
| 当期純利益 | 当期純利益（百万ドル） -71.17769 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 31 July 2018 Advaxis Inc. revenues decreased 52% to $4.9M. Net loss decreased 32% to $47.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative decrease of 79% to $3.6M (expense) Research and Development Expenses decrease of 17% to $36.1M (expense) Other decrease of 31% to $10.9M (expense). |
ADXSのテクニカル分析
ADXSのニュース
Advaxis, Inc. (ADXS: OTCQX U.S.) | Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee 2023/03/03 13:00:35 OTC Markets
Advaxis GAAP EPS of -$8.46, revenue of $0.25M 2023/02/10 12:45:35 Seeking Alpha
Advaxis press release (ADXS): FY GAAP EPS of -$8.46.Revenue of $0.25M, compared with $3.2M for the fiscal year 2021.Cash position On October 31, 2022, the consolidated cash and…
Advaxis and Ayala Pharmaceuticals Complete Merger 2023/01/19 14:37:00 Advaxis
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J. , Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes
Ayala sees last day of trading as merger with Advaxis takes place 2023/01/18 19:24:32 Seeking Alpha
Ayala Pharmaceuticals'' (AYLA) last day of trading is at market close Wednesday as the company''s merger with Advaxis (ADXS) takes place.
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 2023/01/12 13:04:00 businessfortnight.com
Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of […] The post Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 appeared first on Businessfortnight .
Advaxis GAAP EPS of -$1.90, revenue of $0.25M 2022/06/08 12:07:36 Seeking Alpha
Advaxis press release (ADXS): Q2 GAAP EPS of -$1.90.Revenue of $0.25M (-81.8% Y/Y).As of April 30, 2022, the Company had approximately $32.1 million in cash and cash equivalents.
Advaxis (ADXS) Investor Presentation - Slideshow (OTCMKTS:ADXS) 2022/06/04 15:33:36 Seeking Alpha
The following slide deck was published by Advaxis, Inc.
Advaxis to implement one-for-80 reverse split 2022/06/03 20:38:54 Seeking Alpha
Advaxis <> to implement a one-for-80 reverse split of its issued and outstanding common stock
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology 2022/05/26 21:00:00 Advaxis
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® ( pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 2022/05/26 21:00:00 ForexTV
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA® (pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503 being dosed in combination with KEYTRUDA® … The post Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting appeared first on ForexTV .
Advaxis GAAP EPS of -$1.90, revenue of $0.25M 2022/06/08 12:07:36 Seeking Alpha
Advaxis press release (ADXS): Q2 GAAP EPS of -$1.90.Revenue of $0.25M (-81.8% Y/Y).As of April 30, 2022, the Company had approximately $32.1 million in cash and cash equivalents.
Advaxis (ADXS) Investor Presentation - Slideshow (OTCMKTS:ADXS) 2022/06/04 15:33:36 Seeking Alpha
The following slide deck was published by Advaxis, Inc.
Advaxis to implement one-for-80 reverse split 2022/06/03 20:38:54 Seeking Alpha
Advaxis <> to implement a one-for-80 reverse split of its issued and outstanding common stock
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology 2022/05/26 21:00:00 Advaxis
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® ( pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting 2022/05/26 21:00:00 ForexTV
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA® (pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503 being dosed in combination with KEYTRUDA® … The post Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting appeared first on ForexTV .